Orwin John A 4/A

What Happened

• John A. Orwin, a director of First Tracks Biotherapeutics, received equity awards on May 12, 2026: 7,000 stock options and 2,500 restricted stock units (RSUs). Both awards are reported at $0.00 per share (derivative awards), meaning no cash was paid by the reporting person at grant. An amended Form 4 filed June 12, 2026 corrects the original May 14, 2026 filing to show the awards as 7,000 options and 2,500 RSUs.

Key Details

• Transaction date: May 12, 2026; filing: originally May 14, 2026, amended June 12, 2026 to correct award amounts.
• Reported price: $0.00 for both awards (derivative grants; no cash paid by the insider).
• Shares owned after transaction: not disclosed in the filing.
• Footnotes of note:
  • F1: Each RSU converts to 1 share of common stock upon settlement for no consideration.
  • F2: RSUs vest 100% on the date of the issuer's 2027 annual meeting, subject to continued service.
  • F3: Options vest 1/12 monthly beginning June 12, 2026 until fully vested, subject to continued service.
• Filing status: amended to correct award amounts; original Form 4 was filed two business days after the grant and the amendment was later submitted.

Context

• These are grant awards (not open-market purchases or sales) and therefore do not represent an immediate buy/sell signal. RSUs convert to shares at settlement, and the options vest over time (monthly), so any impact on the insider's actual share ownership or potential sales will depend on future vesting and any exercise/settlement decisions.